Losartan Potassium Tablet, Film Coated
Product Images NDC 50090-7794

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 50090-7794). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500907794)

FDA Label Image

Losartanpotassiumfigure1 (Losartanpotassiumfigure1)

Losartanpotassiumfigure1 (Losartanpotassiumfigure1)
This text presents data related to a clinical study comparing the effectiveness of Atenolol and Losartan potassium in reducing the risk of the primary endpoint. The adjusted risk reduction for Losartan potassium is reported to be 13%, with a p-value of 0.021. The study spans 66 months, with measurements taken at 6-month intervals.*
FDA Label Image

Losartanpotassiumfigure2 (Losartanpotassiumfigure2)

FDA Label Image

Losartanpotassiumfigure3 (Losartanpotassiumfigure3)

Losartanpotassiumfigure3 (Losartanpotassiumfigure3)
This text provides results of a medical study comparing the effectiveness of Losartan Potassium and Atenolol in patients over and under 65 years of age with diabetes and a history of cardiovascular disease. The study includes data on the number of patients, event rates, hazard ratios, and outcomes related to stroke. The results suggest that Losartan Potassium may have a favorable impact compared to Atenolol in the studied population.*
FDA Label Image

Losartanpotassiumfigure4 (Losartanpotassiumfigure4)

Losartanpotassiumfigure4 (Losartanpotassiumfigure4)
This text provides data on the percentage of patients with an event in a clinical study comparing Losartan Potassium to a placebo. The risk reduction is calculated to be 16.1%, and the statistical significance is indicated by p=0.022. The study shows that Losartan Potassium may be effective in reducing the occurrence of events compared to a placebo.*
FDA Label Image

Losartanpotassiumstructure (Losartanpotassiumstructure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.